Medrx Co (4586.T) Hisse Fiyat

Medrx Co. Ltd. engages in the business of pharmaceutical drug development based on the transdermal absorption. The company is headquartered in Higashikagawa-Shi, Kagawa-Ken and currently employs 22 full-time employees. The company went IPO on 2013-02-13. The firm produces new medicines based on percutaneous absorption formulation technology. The firm has pharmaceutical formulation technology, including percutaneous absorbent technology of ionic liquid transdermal system (ILTS) using characteristics of ionic liquid, and percutaneous absorbent technology of nano-sized colloid transdermal system (NCTS) using Nano colloidization technology of drug. Based on the technology, The Company aims to maximize drug efficacy, reduce side effects, prevent forgetting to drink, and to administer to patients who are difficult to orally administer, and to produce medicines with new added value.